Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study

Filiz ARDIÇ, (Ağrı Patnos Devlet Hastanesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Ağrı, Türkiye)
Humeyra ÇELİK, (Bolu Abant İzzet Baysal Üniversitesi Tıp Fakültesi, Fizyoloji Anabilim Dalı, Bolu, Türkiye)
Hüseyin YEŞILYURT, (Ankara Şehir Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, Ankara, Türkiye)
Serap Mutlu ÖZÇELİK OTÇU (Sağlık Bilimleri Üniversitesi Gazi Yaşargil Eğitim ve Araştırma Hastanesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Diyarbakır, Türkiye)
Experimental Biomedical Research
3 0
Yıl: 2022 Cilt: 5 Sayı: 1 Sayfa Aralığı: 38 - 47 Metin Dili: İngilizce DOI: 10.30714/j-ebr.2022173849 İndeks Tarihi: 23-06-2022

Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study

Öz:
Aim: To investigate the bisphenol A (BPA) levels, which may be a risk factor in the etiology of endometrioma, in patients diagnosed laparoscopically with endometrioma with and without bowel involvement. Method: In the prospective cross-sectional case control study, 47 cases were included in the study, which were admitted to the gynecology and infertility services with and without bowel involvement endometrioma who were operated and diagnosed histopathologically. 43 patients were included in the control group. For serum BPA value, blood samples taken immediately before the operation were studied in laboratory. Patients and controls were compared with controls in terms of serum BPA values. Results: The mean age of the patients was 35 ± 2 in the endometriosis group and 36 ± 2 in the control group which was and not statistically significant. There was no statistical difference between the patient and control groups in terms of menstruation periods. Serum BPA levels were significantly higher in the bowel involvement group compared to the non-bowel involvement group, as the distribution width was higher due to excessive values, and only 5 patients with bowel involvement did not reach statistically significant levels. Serum BPA level was 1084±1132 ng/L in the endometriosis group and 269±99 ng/L in the control group which was statistically significant (p<0,001). Conclusions: BPA levels were showing very wide range especially in the patient group. Serum BPA levels was statistically significantly higher in the endometrioma group compared to the control group. Therefore, in the etiology of endometriosis BPA may take a definite place.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Matarese G, De Placido G, Nikas Y, et al. Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol Med. 2003;9(5):223– 28.
  • [2] Haydardedeoglu B, Zeyneloglu HB. The impact of endometriosis on fertility. Womens Health. 2015;11:619–23.
  • [3] Kim HS, Kim TH, Chung HH, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer. 2014;110(7):1878–90.
  • [4] Nezhat C, Falik R, McKinney S, et al. Pathophysiology and management of urinary tract endometriosis. Nat Rev Urol. 2017;14(6): 359-72.
  • [5] Sourial S, Tempest N, Hapangama DK. Theories on the pathogenesis of endometriosis. Int J Reprod Med. 2014;2014:179515.
  • [6] Veeraswamy A, Lewis M, Mann A, et al. Extragenital endometriosis. Clin Obstet Gynecol. 2010;53(2):449-66.
  • [7] Kabir ER, Rahman MS, Rahman I. A review on endocrine disruptors and their possible impacts on human health. Environ Toxicol Pharmacol. 2015;40(1):241–58.
  • [8] Heindel JJ, Newbold R, Schug TT. Endocrine disruptors and obesity. Nat Rev Endocrinol. 2015;11(11):653–61.
  • [9] Sweeney MF, Hasan N, Soto AM, et al. Environmental endocrine disruptors: effects on the human male reproductive system. Rev Endocr Metab Disord. 2015;16(4):341–57.
  • [10] Costa EM, Spritzer PM, Hohl A, et al. Effects of endocrine disruptors in the development of the female reproductive tract. Arq Bras Endocrinol Metab. 2014;58(2):153–61.
  • [11] Chevalier N, Fenichel P. Endocrine disruptors: new players in the pathophysiology of type 2 diabetes? Diabetes Metab. 2015;41(2):107–15.
  • [12] Knower KC, To SQ, Leung YK, et al. Endocrine disruption of the epigenome: a breast cancer link. Endocr Relat Cancer. 2014;21(2):33–55.
  • [13] Ballesteros G, Soledat P, Perez-Bendito D. Analytical methods for the determination of bisphenol A in food. J Chromatogram A. 2009; 1216(3): 449-69.
  • [14] Tsai W-T. Human health risk on environmental exposure to Bisphenol-A: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2006; 24(2): 225- 55.
  • [15] Matsumoto A, Kunugita N, Kitagawa K, et al. Bisphenol A levels in human urine. Environ Health Perspect. 2003; 111(1): 101.
  • [16] Garcı́a RS and Losada PP. Determination of bisphenol A diglycidyl ether and its hydrolysis and chlorohydroxy derivatives by liquid chromatography–mass spectrometry. J Chromatogr A. 2004; 1032(1-2): 37-43.
  • [17] Caserta D, Mantovani A, Marci R, et al. Environment and women's reproductive health. Hum Reprod Update. 2011; 17(3): 418-33.
  • [18] Alonso-Magdalena P, Laribi O, Ropero AB, et al. Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic α-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect. 2005;113(8): 969.
  • [19] Moriyama K, Tagami T, Akamizu T, et al. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab. 2002; 87(11): 5185-90.
  • [20] Wetherill YB, Fisher NL, Staubach A, et al. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res. 2005; 65(1): 54- 65.
  • [21] Lopez-Cervantes J and Paseiro-Losada P. Determination of bisphenol A in, and its migration from, PVC stretch film used for food packaging. Food Addit Contam. 2003; 20(6): 596-606.
  • [22] Lee J, Choi K, Park J, et al. Bisphenol A distribution in serum, urine, placenta, breast milk, and umbilical cord serum in a birth panel of mother–neonate pairs. Sci Total Environ. 2018; 626: 1494-1501. [23] Ginsberg G and Rice DC. Does rapid metabolism ensure negligible risk from bisphenol A? Environ Health Perspect. 2009; 117(11): 1639.
  • [24] Vinatier D, Orazi G, Gosson M, et al. Theories of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2001; 96(1): 21-34.
  • [25] Matsuura K, Ohtake H, Katabuchi H, et al. Coelomic metaplasia theory of endometriosis: evidence from in vivo studies and an in vitro experimental model. Gynecol Obstetric Invest. 1999; 47(1): 18-22.
  • [26] Signorile PG, Spugnini EP, Mita L, et al. Pre-natal exposure of mice to bisphenol A elicits an endometriosis-like phenotype in female offspring. Gen Comp Endocrinol. 2010; 168(3): 318-25.
  • [27] Vercellini P. Vigano P, Somigliana E, et al. ‘Endometriosis: Pathogenesis and treatment’, Nat Rev Endocrinol. 2014;10(5), 261–75.
  • [28] Tanbo T and Fedorcsak P. ‘Endometriosisassociated infertility: aspects of pathophysiological mechanisms and treatment options’, Acta Obstet Gynecol Scand. 2017;96(6) 659–67.
  • [29] Shafrir, A. L. Farland LV, Shah DK, et al. ‘Risk for and consequences of endometriosis: A critical epidemiologic review’. Best Pract and Res Clin Obste and Gynaecol. 2018; 51:1–15.
  • [30] Nnoaham KE, Webster P, Kumbang J, et al. ‘Is early age at menarche a risk factor for endometriosis? A systematic review and meta-analysis of case-control studies’, Fertil Steril. 2012; 98(3):702-12.
  • [31] Matalliotakis I M, Cakmak H, Fragouli YG, et al. ‘Epidemiological characteristics in women with and without endometriosis in the Yale series’. Arch Gynecol Obstet. 2008; 277(5): 389–93.
  • [32] Moini A, Malekzadeh F, Amirchaghmaghi E, et al. ‘Risk factors associated with endometriosis among infertile Iranian women’. Arch Med Sci. 2013 Jun 20;9(3):506-14.
  • [33] Darrow SL, Vena JE, Batt RE, et al. Menstrual cycle characteristics and the risk of endometriosis. Epidemiology. 1993;4(2):135-42.
  • [34] Cobellis L, Colacurci N, Trabucco E, et al. Measurement of bisphenol A and bisphenol B levels in human blood sera from healthy and endometriotic women. Biomed Chromatogr. 2009 ;23(11):1186-90.
  • [35] Redwine DB. Ovarian endometriosis: a marker for more extensive pelvic and intestinal disease. Fertil Steril. 1999;72(2):310-15.
  • [36] Yong PJ, Bedaiwy MA, Alotaibi F, et al. Pathogenesis of bowel endometriosis. Best Pract Res Clin Obstet Gynaecol. 2021;71:2- 13.
  • [37] Rashidi BH, Amanlou M, Lak TB, et al. A case-control study of bisphenol A and endometrioma among subgroup of Iranian women. J Res Med Sci. 2017;22:7.
  • [38] 38 Upson K, Sathyanarayana S, De Roos AJ, et al. A population-based case-control study of urinary bisphenol A concentrations and risk of endometriosis. Hum Reprod. 2014 ;29(11):2457-64.
  • [39] Itoh H, Iwasaki M, Hanaoka T, et al. Urinary bisphenol-A concentration in infertile Japanese women and its association with endometriosis: A cross-sectional study. Environ Health Prev Med. 2007;12(6):258- 64.
  • [40] Buck Louis GM, Peterson CM, Chen Z, et al. Bisphenol A and phthalates and endometriosis: the Endometriosis: Natural History, Diagnosis and Outcomes Study. Fertil Steril. 2013;100(1):162-9.e1-2.
  • [41] Jones RL, Lang SA, Kendziorski JA, et al. Use of a Mouse Model of Experimentally Induced Endometriosis to Evaluate and Compare the Effects of Bisphenol A and Bisphenol AF Exposure. Environ Health Perspect. 2018;126(12):127004.
  • [42] Li Y, Perera L, Coons LA, et al. Differential in Vitro Biological Action, Coregulator Interactions, and Molecular Dynamic Analysis of Bisphenol A (BPA), BPAF, and BPS Ligand-ERα Complexes. Environ Health Perspect. 2018;126(1):017012.
  • [43] Peinado FM, Lendínez I, Sotelo R, et al. Association of Urinary Levels of Bisphenols A, F, and S with Endometriosis Risk: Preliminary Results of the EndEA Study. Int J Environ Res Public Health. 2020;17(4):1194.
APA ardıç f, ÇELİK H, Yeşilyurt H, OTÇU S (2022). Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. , 38 - 47. 10.30714/j-ebr.2022173849
Chicago ardıç filiz,ÇELİK HÜMEYRA,Yeşilyurt Hüseyin,OTÇU Serap Mutlu ÖZÇELİK Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. (2022): 38 - 47. 10.30714/j-ebr.2022173849
MLA ardıç filiz,ÇELİK HÜMEYRA,Yeşilyurt Hüseyin,OTÇU Serap Mutlu ÖZÇELİK Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. , 2022, ss.38 - 47. 10.30714/j-ebr.2022173849
AMA ardıç f,ÇELİK H,Yeşilyurt H,OTÇU S Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. . 2022; 38 - 47. 10.30714/j-ebr.2022173849
Vancouver ardıç f,ÇELİK H,Yeşilyurt H,OTÇU S Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. . 2022; 38 - 47. 10.30714/j-ebr.2022173849
IEEE ardıç f,ÇELİK H,Yeşilyurt H,OTÇU S "Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study." , ss.38 - 47, 2022. 10.30714/j-ebr.2022173849
ISNAD ardıç, filiz vd. "Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study". (2022), 38-47. https://doi.org/10.30714/j-ebr.2022173849
APA ardıç f, ÇELİK H, Yeşilyurt H, OTÇU S (2022). Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. Experimental Biomedical Research, 5(1), 38 - 47. 10.30714/j-ebr.2022173849
Chicago ardıç filiz,ÇELİK HÜMEYRA,Yeşilyurt Hüseyin,OTÇU Serap Mutlu ÖZÇELİK Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. Experimental Biomedical Research 5, no.1 (2022): 38 - 47. 10.30714/j-ebr.2022173849
MLA ardıç filiz,ÇELİK HÜMEYRA,Yeşilyurt Hüseyin,OTÇU Serap Mutlu ÖZÇELİK Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. Experimental Biomedical Research, vol.5, no.1, 2022, ss.38 - 47. 10.30714/j-ebr.2022173849
AMA ardıç f,ÇELİK H,Yeşilyurt H,OTÇU S Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. Experimental Biomedical Research. 2022; 5(1): 38 - 47. 10.30714/j-ebr.2022173849
Vancouver ardıç f,ÇELİK H,Yeşilyurt H,OTÇU S Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study. Experimental Biomedical Research. 2022; 5(1): 38 - 47. 10.30714/j-ebr.2022173849
IEEE ardıç f,ÇELİK H,Yeşilyurt H,OTÇU S "Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study." Experimental Biomedical Research, 5, ss.38 - 47, 2022. 10.30714/j-ebr.2022173849
ISNAD ardıç, filiz vd. "Bisphenol A levels in bowel endometrioma diagnosed serums: A case control study". Experimental Biomedical Research 5/1 (2022), 38-47. https://doi.org/10.30714/j-ebr.2022173849
Sayfa Oluşturulma Tarihi
18-04-2024 1:9

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları